PT  - JOURNAL ARTICLE
AU  - García-Albéniz, Xabier
AU  - Amo, Julia del
AU  - Polo, Rosa
AU  - Morales-Asencio, José Miguel
AU  - Hernán, Miguel A
TI  - Brief communication: A meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19
AID  - 10.1101/2020.09.29.20203869
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.09.29.20203869
4099  - http://medrxiv.org/content/early/2020/10/01/2020.09.29.20203869.short
4100  - http://medrxiv.org/content/early/2020/10/01/2020.09.29.20203869.full
AB  - Background Recruitment into randomized trials of hydroxychloroquine (HCQ) for prevention of COVID-19 is being threatened by a widespread conviction that HCQ is not effective for prevention. In the absence of an updated systematic review, we conducted a meta-analysis of randomized trials that study the effectiveness of HCQ to prevent COVID-19.Methods and Findings A search of PubMed, Embase, and medRxiv with expert consultation found four completed randomized trials: two pre-exposure prophylaxis trials and two post-exposure prophylaxis trials. We obtained or calculated the risk ratio of COVID-19 diagnosis for assignment to HCQ versus no HCQ (either placebo or usual care) for each trial, and then pooled the risk ratio estimates. The risk ratio estimated for each of the individual trials were 0.74 (95% CI 0.50-1.10), 0.95 (0.25, 3.64), 0.83 (95% CI: 0.58-1.18), and 0.69 (95% CI: 0.35-1.37). The pooled risk ratio estimate was 0.78 (95% CI: 0.61-0.99). All four trials found a similar rate of adverse effects in the HCQ and no HCQ groups.Discussion A pooled analysis of these randomized trials cannot rule out a moderate reduction of COVID-19 risk after assignment to HCQ. Yet the findings from the randomized trials were widely interpreted as definite evidence of lack of effectiveness of HCQ, simply because they were not “statistically significant”. Completion of the ongoing trials is needed to generate more precise estimates of the effectiveness of HCQ to prevent COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was not fundedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used in the analysis are publicly available